



13 March 2025

**ImmuPharma PLC**  
("ImmuPharma" or the "Company")

### **ImmuPharma proves unique Mechanism of Action of P140**

ImmuPharma PLC (LSE:IMM), a leading specialist in peptide based drug discovery and development, announces a significant milestone in evidencing the unique mechanism of action ("MOA") of its P140 autoimmune technology platform.

Importantly, these new discoveries announced today, in respect to the MOA of P140, highlight that:

- **P140 has a unique MOA:** The results provide direct evidence for the first time of a major key hypothesis of the unique MOA of P140.
- **P140 is non-immunosuppressive:** Unlike the most advanced therapies currently available for the treatment of autoimmune diseases, these findings indicate that P140 does not reduce or block the body's ability to mount a specific immune response.
- **P140 is effective and safe:** These findings confirm P140's potential as a safe and effective treatment for patients suffering from systemic lupus erythematosus (SLE).

These discoveries result from a new preclinical study designed by ImmuPharma Biotech's team and conducted at a world leading Laboratory in the USA. While detailed data will be released in due course, these findings allow ImmuPharma to further expand its intellectual property portfolio, with additional new patents, strengthening the commercial viability of the P140 technology platform.

Relevant therapy markets in this area are forecast to reach global sales of c.\$360 billion by 2030. There have been 11 relevant therapy product licensing deals averaging \$1bn total deal value in last 2 years. (UBS Investment Banking Reports).

**Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma, said:**  
*"These stunning results clearly demonstrate the unique MOA of P140 and this data adds significantly to our ongoing discussions with potential partners and our objective to secure the optimum deal(s) for our shareholders."*

**Commenting on this announcement, Sébastien Goudreau, CEO of ImmuPharma Biotech, said:**  
*"These results are extremely compelling. Not only do they validate our MOA, they also indicate that P140 has the possibility to become a central treatment for a number of autoimmune diseases. Patients can be very hopeful, I certainly am!"*

Ends

*This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On*

*publication of this announcement via a regulatory information service, this information is considered to be in the public domain.*

For further information please contact:

<b>ImmuPharma PLC</b> ( <a href="http://www.immupharma.co.uk">www.immupharma.co.uk</a> )	+44 (0) 207 206 2650
Tim McCarthy, Chief Executive Officer	
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
<b>SPARK Advisory Partners Limited (NOMAD)</b>	+44 (0) 203 368 3550
Neil Baldwin	
<b>Stanford Capital Partners (Joint Broker)</b>	+44 (0) 20 3650 3650
Patrick Claridge, Bob Pountney	
<b>SI Capital (Joint Broker)</b>	+44 (0) 1483 413500
Nick Emerson	

## Notes to Editors

### About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a unique non-immunosuppressive peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases.

### About Lupus (Systemic Lupus Erythematosus / SLE)

Lupus is a chronic inflammatory disease which is thought to affect some 16 million individuals worldwide. The current standard of care still consists of steroid and anti-malarial therapies which have side-effects and poor response in many patients. Recently more targeted monoclonal therapies are GlaxoSmithKline's Benlysta and more recently, AstraZeneca's Saphnelo. There still exists a high unmet medical need for a drug that has a strong efficacy and safety profile.

For additional information about ImmuPharma please visit [www.immupharma.co.uk](http://www.immupharma.co.uk)

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.